Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Infect Med (Beijing) ; 3(1): 100086, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38352920

RESUMO

A 68-year-old-gentleman presented with left hip pain, night sweats, fatigue, and weight loss. He had previously experienced pain with white discharge until he underwent an arthroscopic washout and reduction. The left lower limb was shortened and wasted with limited hip movements. He had recently travelled to Zambia, his country of origin. Imaging demonstrated a large mass with chronic erosions of the acetabulum and femoral head. Synovial biopsy grew Mycobacterium tuberculosis, which was treated with rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months then 4 months of rifampicin and isoniazid. Whole genome sequencing indicated full sensitivity. Complex reconstructive surgery is scheduled, with a custom femoral head and acetabulum. This case illustrates the importance of considering tuberculosis in patients with erosive joint pathology and a multidisciplinary approach as delayed diagnosis results in high morbidity. Prompt diagnosis using newer modalities such as whole genome sequencing on synovial fluid can enable timely treatment.

2.
J Infect ; 69(5): 440-6, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24975177

RESUMO

OBJECTIVE: Bacterial meningitis in sub-Saharan Africa is predominantly caused by Streptococcus pneumoniae, is often associated with HIV co-infection and mortality rates are double those seen in better resourced settings. METHODS: To investigate the cause of this excessive mortality we quantified the pneumococcal DNA load and six common pro-inflammatory cytokines in the cerebrospinal fluid (CSF) of Malawian adults with culture proven pneumococcal meningitis and correlated the results to clinical parameters and outcome. There are currently no published data relating bacterial load to outcome in adults with pneumococcal meningitis. RESULTS: The mean age of patients was 32 years, 82% were HIV infected and 49% had died by day 40. CSF bacterial loads were high (median 6.5 × 10(5) copies/ml CSF) and there was no significant variation in bacterial load between survivors and non-survivors. All pro-inflammatory CSF cytokines were elevated in the CSF, with no clinically important differences between survivors and non-survivors. HIV status did not affect the CSF bacterial load or cytokine response. CONCLUSION: Mortality from pneumococcal meningitis in adults in sub-Saharan Africa is not related to pneumococcal bacterial load. More research is needed to understand the very high mortality from meningitis in this region.


Assuntos
Carga Bacteriana , Citocinas/líquido cefalorraquidiano , Meningite Pneumocócica/mortalidade , Streptococcus pneumoniae/isolamento & purificação , Adulto , Coinfecção/microbiologia , Coinfecção/virologia , DNA Bacteriano/líquido cefalorraquidiano , Feminino , Infecções por HIV/complicações , Humanos , Malaui/epidemiologia , Masculino , Meningite Pneumocócica/líquido cefalorraquidiano , Meningite Pneumocócica/complicações , Meningite Pneumocócica/microbiologia , Streptococcus pneumoniae/genética , Adulto Jovem
3.
Cochrane Database Syst Rev ; (3): CD008806, 2013 Mar 28.
Artigo em Inglês | MEDLINE | ID: mdl-23543568

RESUMO

BACKGROUND: Every day children and adults throughout the world die from acute community-acquired bacterial meningitis, particularly in low-income countries. Survivors are at risk of deafness, epilepsy and neurological disabilities. Osmotic therapies have been proposed as an adjunct to improve mortality and morbidity from bacterial meningitis. The theory is that they will attract extra-vascular fluid by osmosis and thus reduce cerebral oedema by moving excess water from the brain into the blood. The intention is to thus reduce death and improve neurological outcomes. OBJECTIVES: To evaluate the effects on mortality, deafness and neurological disability of osmotic therapies added to antibiotics for acute bacterial meningitis in children and adults. SEARCH METHODS: We searched CENTRAL 2012, Issue 11, MEDLINE (1950 to November week 3, 2012), EMBASE (1974 to November 2012), CINAHL (1981 to November 2012), LILACS (1982 to November 2012) and registers of ongoing clinical trials (April 2012). We also searched conference abstracts and contacted researchers in the field. SELECTION CRITERIA: Randomised controlled trials testing any osmotic therapy in adults or children with acute bacterial meningitis. DATA COLLECTION AND ANALYSIS: Two review authors independently screened the search results and selected trials for inclusion. We collected data from each study for mortality, deafness, seizures and neurological disabilities. Results are presented using risk ratios (RR) and 95% confidence intervals (CI) and grouped according to whether the participants received steroids or not. MAIN RESULTS: Four trials were included comprising 1091 participants. All compared glycerol (a water-soluble sugar alcohol) with a control; in three trials this was a placebo, and in one a small amount of 50% dextrose. Three trials included comparators of dexamethasone alone or in combination with glycerol. As dexamethasone appeared to have no modifying effect, we aggregated results across arms where both treatment and control groups received corticosteroids and where both treatment and control groups did not.Compared to placebo, glycerol may have little or no effect on death in people with bacterial meningitis (RR 1.09, 95% confidence interval (CI) 0.89 to 1.33, 1091 participants, four trials, low-quality evidence); or on death and neurological disability combined (RR 1.04, 95% CI 0.86 to 1.25).Glycerol may have little or no effect on seizures during treatment for meningitis (RR 1.08, 95% CI 0.90 to 1.30, 909 participants, three trials, low-quality evidence).Glycerol may reduce the risk of subsequent deafness (RR 0.60, 95% CI 0.38 to 0.93, 741 participants, four trials, low-quality evidence). AUTHORS' CONCLUSIONS: The only osmotic diuretic to have undergone randomised evaluation is glycerol. Data from trials to date have not demonstrated benefit on death, but it may reduce deafness. Osmotic diuretics, including glycerol, should not be given to adults and children with bacterial meningitis unless as part of carefully conducted randomised controlled trial.


Assuntos
Diuréticos Osmóticos/uso terapêutico , Glicerol/uso terapêutico , Meningites Bacterianas/terapia , Adolescente , Corticosteroides/uso terapêutico , Adulto , Antibacterianos/uso terapêutico , Criança , Terapia Combinada/métodos , Infecções Comunitárias Adquiridas/complicações , Infecções Comunitárias Adquiridas/metabolismo , Infecções Comunitárias Adquiridas/mortalidade , Infecções Comunitárias Adquiridas/terapia , Surdez/prevenção & controle , Dexametasona/uso terapêutico , Epilepsia/prevenção & controle , Glucose/uso terapêutico , Humanos , Pressão Intracraniana/fisiologia , Meningites Bacterianas/complicações , Meningites Bacterianas/metabolismo , Meningites Bacterianas/mortalidade , Osmose/fisiologia , Pressão Osmótica/fisiologia , Ensaios Clínicos Controlados Aleatórios como Assunto
4.
J Infect Dis ; 205(1): 106-10, 2012 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-22075766

RESUMO

Mortality from adult bacterial meningitis exceeds 50% in sub-Saharan Africa. We postulated that-particularly in individuals infected with human immunodeficiency virus (HIV)-herpes simplex virus, varicella zoster virus, Epstein-Barr virus (EBV), and cytomegalovirus (CMV) in the cerebrospinal fluid (CSF) contribute to poor outcome. CSF from 149 Malawian adults with bacterial meningitis and 39 controls were analyzed using polymerase chain reaction. EBV was detected in 79 of 149 bacterial meningitis patients. Mortality (54%) was associated with higher CSF EBV load when adjusted for HIV (P = .01). CMV was detected in 11 of 115 HIV-infected patients, 8 of whom died. The mechanisms by which EBV and CMV contribute to poor outcome require further investigation.


Assuntos
Coinfecção/mortalidade , Infecções por Citomegalovirus/complicações , Citomegalovirus/isolamento & purificação , Infecções por Vírus Epstein-Barr/complicações , Herpesvirus Humano 4/isolamento & purificação , Meningites Bacterianas/mortalidade , Adolescente , Adulto , Idoso , Estudos de Casos e Controles , Coinfecção/líquido cefalorraquidiano , Coinfecção/complicações , Coinfecção/epidemiologia , Citomegalovirus/genética , Infecções por Citomegalovirus/líquido cefalorraquidiano , DNA Viral/líquido cefalorraquidiano , Infecções por Vírus Epstein-Barr/líquido cefalorraquidiano , Feminino , Infecções por HIV/líquido cefalorraquidiano , Infecções por HIV/complicações , Infecções por HIV/epidemiologia , Herpesvirus Humano 1/genética , Herpesvirus Humano 1/isolamento & purificação , Herpesvirus Humano 2/genética , Herpesvirus Humano 2/isolamento & purificação , Herpesvirus Humano 3/genética , Herpesvirus Humano 3/isolamento & purificação , Herpesvirus Humano 4/genética , Humanos , Modelos Logísticos , Malaui , Masculino , Meningites Bacterianas/líquido cefalorraquidiano , Meningites Bacterianas/complicações , Pessoa de Meia-Idade , Reação em Cadeia da Polimerase , Prevalência , Estudos Prospectivos , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...